Novo Nordisk has already applied in the U.S. and EU to expand the pill's approval to include lowering the risk of serious cardiovascular complications, Stephen Gough, the company's global chief medical officer, said in an interview. Rybelsus is the once-daily oral formulation of Novo Nordisk's blockbuster diabetes injection Ozempic, which is taken once a week. Both treatments, as well as the company's weekly weight loss injection Wegovy, contain the active ingredient semaglutide. Wegovy in March 2024 won U. ...